Fig. 4.

CXCL12 gene expression by RT-PCR at the end of RTCT (30 Gy in 2 Gy daily fractions for 3 weeks plus cisplatin 4 mg/kg weekly) and concurrent (a) or adjuvant (c) plerixafor (5 mg/kg/day by continuous sc infusion) in OCICx 20. Also shown is protein expression by IHC for pCXCR4 and downstream pERK, markers of MDSC (Ly6G) and macrophage (F4/80) intratumoral accumulation and PD-L1 at the end of concurrent (b) and adjuvant (d) treatment. The full IHC dataset for the concurrent experiment with additional markers is in Supplemental Fig. 1. Protein expression is shown as the mean ( ± standard error) of the percentage of the tumour cell or stromal surface area that stained positively. pCXCR4, pERK and PD-L1 were predominantly expressed in tumour cell regions, whereas Ly6G and F4/80 were expressed in stroma. The CXCL12 gene expression results are for two tumours per treatment group. The IHC results are for 7–12 tumours per treatment group. RT, radiotherapy; RTCT, radiotherapy and concurrent cisplatin; RTCT + P, RTCT + concurrent or adjuvant plerixafor; ^p < 0.05 relative to controls; *p < 0.05 relative to RTCT